ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

MDX Meldex

7.09
0.00 (0.00%)
05 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Meldex LSE:MDX London Ordinary Share GB0032681628 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 7.09 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Change of Adviser

29/08/2008 8:00am

UK Regulatory


    RNS Number : 2726C
  Meldex International PLC
  29 August 2008
   

 For Immediate Release  29 August 2008


    Meldex International Plc ("Meldex " or "the Company")

    Change of Adviser

    The Company is pleased to announce the appointment of FinnCap as nominated adviser and broker with immediate effect.



    For further information:

 Meldex International Plc  + 44 (0) 20 7098 9880

 Buchanan Communications   + 44 (0) 20 7466 5000

 FinnCap, NOMAD             + 44 (0)20 7600 1658



    About FinnCap
    FinnCap is an independent institutional broker and nominated adviser. FinnCap has 45 retained clients today and was the top ranked nomad
by client wins in 2007. FinnCap has a strong track record in advisory services and raising capital and looks to provide high quality
research and after market care to growth companies.  


    About Meldex International Plc
    Meldex International plc is an innovative specialty pharmaceutical and OTC product. Listed on London's AIM in May 2003, the Company has
over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with
several global healthcare companies. Meldex has acquired sales and marketing resources within Europe and the US as a launch mechanism for
its own pharmaceutical products. Meldex acquired the Melbrosin business in June 2007. Melbrosin's focus is on consumer over the counter
health care products based on substances of natural and plant origin which are developed into consumer orientated brands then scaled,
produced and distributed by Melbrosin. The Melbrosin complements the prescription pharmaceutical sales and marketing business created and
expanded in 2006.

    The business continues to develop innovative delivery mechanisms enhancing both its own product range and those of selected partners
using its proprietary XGELTM polymer technology. For further information please go to www.meldexinternational.com




This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
APPFGGZRZRZGRZZ

1 Year Meldex Chart

1 Year Meldex Chart

1 Month Meldex Chart

1 Month Meldex Chart

Your Recent History

Delayed Upgrade Clock